Novo Nordisk AS (HAM:NOV) Net Interest Margin (Bank Only) %


HAM:NOV Novo Nordisk AS HAM:NOV
84 GF Score
Price €43.43
GF Value €120.52
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Novo Nordisk AS Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

HAM:NOV
84GF Score
Novo Nordisk AS HAM:NOV
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Novo Nordisk AS (HAM:NOV) Overvalued in 2026?

Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued. The current stock price of €43.43 is trading 64% below its estimated GF Value™ of €120.52. GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.

Key valuation signals for HAM:NOV:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €120.52 vs. price of €43.43 (64% below fair value)
  • GF Score™: 84/100 with 4 warning signs

No single metric tells the full story. See the HAM:NOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novo Nordisk AS Business Description

Address Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
84GF Score

Get the complete analysis for HAM:NOV

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€43.43
Price
€120.52
GF Value